A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

NCT02363491 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
96
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Opsona Therapeutics Ltd.

Collaborators